CAR T-cell therapy, CB-011, on FDA fast track for hard-to-treat myeloma
The U.S. Food and Drug Administration (FDA) has given a fast track designation to CB-011, an experimental CAR T-cell therapy being developed by…
News
New mouse models may accelerate multiple myeloma research
More than a dozen new mouse models of multiple myeloma, which researchers hope will advance understanding and treating the disease, were described in a…
ISB 1442 antibody therapy wins US orphan drug status
ISB 1442, Ichnos Sciences’Â investigational bi-specific antibody-based treatment, has earned orphan drug designation from the U.S. Food and Drug Administration (FDA) for treating relapsed or…
EasyM, blood test for residual myeloma activity, certified in US
Multiple myeloma patients in the U.S. will now have access to Rapid Novor‘s noninvasive and highly sensitive blood test for monitoring minimal residual…
Fatty acid-binding proteins may be potential target for myeloma
Blocking the activity of a group of proteins called fatty acid-binding proteins (FABPs) may be a useful treatment strategy for multiple myeloma, a new…
Prominent voices to help spotlight myeloma risk in Black communities
Janssen and radio host and comedian D.L. Hughley are partnering to call attention to multiple myeloma in Black communities, with a goal of…
Goal of Myeloma Action Month? Telling the community’s stories.
For this Myeloma Action Month (MAM), observed each March to call attention to multiple myeloma and those affected by the blood disorder, the…
Elranatamab under FDA priority review for hard-to-treat myeloma
The U.S. Food and Drug Administration (FDA) has granted priority review to Pfizer‘s application of its investigational under-the-skin therapy elranatamab for people with relapsed…
IASO Biotherapeutics’ CAR T-cell therapy gets fresh FDA support
The U.S. Food and Drug Administration (FDA) has granted fast track and regenerative medicine advanced therapy designations to CT103A, IASO Biotherapeutics’ experimental CAR T-cell therapy…
Abecma cuts worse outcomes risk in half in hard-to-treat myeloma cases
Abecma (idecabtagene vicleucel or ide-cel) reduced the risk of disease progression or death by half in adults with relapsed or refractory multiple myeloma…
